Introduction {#sec1}
============

RNA vaccination is an expanding field with applications from cancer immunotherapy, infectious diseases, tissue regeneration and protein replacement therapy.[@bib1], [@bib2], [@bib3] Contrary to DNA, RNA does not need to cross the nuclear envelope for expression, a feature that results in higher transfection efficiency over DNA of differentiated or non-dividing cells such as neurons[@bib4], [@bib5], [@bib6] or dendritic cells.[@bib7] However, nuclease degradation and inefficient or short-time expression of RNA still limits its application.[@bib1], [@bib8] While local intranodal injection of RNA results in effective induction of a specific immune response,[@bib9], [@bib10], [@bib11] intramuscular (i.m.), subcutaneous, or intravenous (i.v.) injections would be preferred for large-scale preventive vaccination. For that, different types of nanoparticles, from micelles to lipidic nanoparticle RNA-encoded antigens, need to be presented to lymphocytes by dendritic cells (DCs) to induce an immune response against cancer or viruses.[@bib1], [@bib12] Liposome- or lipidic nanoparticle-mediated delivery of RNA encoding cancer or viral antigens resulted in protective immune responses in several models (mice and Macaque) and in humans.[@bib1], [@bib7], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23] Among the strategies aimed at inducing antigenic presentation by antigen-presenting cells, systemic delivery of RNA to splenic DCs reached clinical trials.[@bib16], [@bib24] Kranz et al.[@bib16] used negatively-charged unPEGylated lipoplexes without ligand, which selectively accumulate in the spleen to transfect splenic DCs and induce a protective immune response against melanoma. Our group has developed ternary complexes comprising a cationic polymer and mannosylated liposomes, designated lipopolyplexes (LPPs), for mRNA delivery to splenic DCs.[@bib25] We previously demonstrated that mRNA LPPs show superior immunogenicity and effectiveness in controlling tumor growth over mRNA lipoplexes and mRNA polyplexes.[@bib15], [@bib26] The first generation of mannosylated LPPs were formed with the PEGylated histidylated polylysine (PEG-HpK) cationic polymer and lipophosphoramidate liposomes made with N-methyl imidazolium lipophosphoramidate (cationic lipid), histamine lipophosphoramidate (protonable lipid), and a mannosylated lipid to favor endocytosis by DCs.[@bib7] The second generation of mannosylated LPPs were also formed with the PEG-HpK polymer and lipophosphoramidate liposomes but included a glycolipid containing a tri-antenna of α-D-mannopyranoside instead of a monovalent mannose for improved endocytosis by DCs.[@bib27] Cationic and mannosylated LPPs exerted powerful anti-tumor effects when used as therapeutic vaccine in different experimental tumor models.[@bib14], [@bib15]

In addition to complexing conventional mRNA into stable nanoparticles, a further improvement in RNA vaccination could be gained by the use of self-amplifying RNA or Replicon RNA (RepRNA), particularly for RNA vaccines against influenza.[@bib28], [@bib29] Auto-amplifying RepRNA is generated from a viral genome, a positive-RNA strand that bears the ability to replicate and translate without generating infectious progeny because it lacks at least one structural gene.[@bib30], [@bib31] Compared with mRNA, RepRNA allows amplification of RNA copies in the cytoplasm of host cells, which offer several rounds of antigen production.[@bib32], [@bib33], [@bib34], [@bib35] As there are no DNA intermediates, there is no risk of integration. Injection of RepRNA extends the duration and magnitude of antigen expression compared to mRNA, giving equivalent protection against influenza at lower doses than mRNA.[@bib3], [@bib26], [@bib36], [@bib37] Since RepRNA based-vaccination is a more recent strategy than vaccination with mRNA, there are few formulations developed for their delivery.[@bib1], [@bib3], [@bib28]

In this study, we evaluated the capability of neutrally charged LPPs, including a mannosylated lipid, to transfect DCs.[@bib7], [@bib14], [@bib15] We determined the physico-chemical properties of LPPs and their efficiency to transfect DCs both *in vitro* and *in vivo*. Administration of LPPs prepared with conventional RNA or self-replicative RNA resulted in reporter gene expression in mice and the induction of an antigen-specific immune response when LPPs were prepared with RNA encoding an influenza antigen.

Results and Discussion {#sec2}
======================

Formation of Neutral RNA LPPs {#sec2.1}
-----------------------------

A majority of previous studies reported the functionality upon *in vivo* injection of either positively-charged[@bib7], [@bib15], [@bib38] or negatively-charged[@bib16], [@bib39] RNA complexes. In this study, we chose to use a neutral formulation, as they are known to have benefits over the others. Since, neutral RNA lipoplexes are unstable,[@bib16] we used an LPP strategy to form neutral RNA complexes. We produced neutral nanoparticles that would benefit from their prolonged blood circulation compared to positively-charged and negatively-charged nanoparticles.[@bib40], [@bib41], [@bib42], [@bib43], [@bib44] Neutral nanoparticles show negligible protein adsorption and decreased complement activation compared to positive and negative ones.[@bib40], [@bib42], [@bib45] Combined with PEGylation of the liposomes, the neutral surface is expected to extend blood circulation and increase the chances of nanoparticle retention in the desired organs after i.v. injection.[@bib42], [@bib44], [@bib46] Neutral charge is also expected to favor the penetration of the extracellular matrix and distribution to lymphatics for enhanced delivery to lymph nodes after interstitial (i.m.) injection.[@bib47], [@bib48], [@bib49]

The formation of LPPs is described in [Figure 1](#fig1){ref-type="fig"}. LPPs consist in a tripartite mix of RNA, a polymer, and liposomes. To form LPPs without cationic lipids, we first complexed RNA with polyethylenimine (PEI), the most frequently used polymer in LPP formulations,[@bib50], [@bib51], [@bib52] before adding anionic liposomes. As shown in [Table 1](#tbl1){ref-type="table"}, polyplexes prepared at N/P ratios 4.5--9 had mean diameters of 150--170 nm. We selected an N/P ratio of 6, yielding complexes of 166 nm and +20 mV. For the anionic liposomes, we used monodisperse liposomes containing 5% 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-\[carboxy(polyethylene glycol)-2000\] (DSPE-PEG) to provide stability in biological fluids,[@bib53], [@bib54] 40% molar negatively charged 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA) to favor interaction with the positively charged polyplex and for immunogenicity,[@bib55], [@bib56] the fusiogenic lipid 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) to promote endosomal escape,[@bib57] and a mannosylated lipid (16:0 1,2-dipalmitoyl-sn-glycero-3-phospho((ethyl-1',2′,3′-triazole)triethyleneglycolmannose \[PA-PEG3-mannose\]) to engage the mannose receptor on dendritic cells.[@bib7], [@bib31] We fixed the total PEGylated lipid content at 10% (5% DSPE-PEG + 5% PEG-mannose) to decrease non-specific accumulation based on previous studies.[@bib54], [@bib58], [@bib59] In line with the results of Kranz et al.[@bib16] on splenic DC transfection with RNA lipoplexes, 40% DOPE helper lipid was included. Liposomes were monodisperse with a diameter of 140--150 nm and a polydispersity index (PDI; measure of size distribution) below 0.2 (PDI 0.14/0.05) and a negative charge of −18/6 mV. Next, we determined the liposome/PEI ratio yielding neutral LPPs ([Table 2](#tbl2){ref-type="table"}). Entrapping the polyplexes increased the liposome diameter from 140 to 160--190 nm and decreased the size distribution, resulting in monodisperse LPPs (PDI 0.13--0.15), features observed previously.[@bib14], [@bib60], [@bib61] Moreover, formation of LPPs shielded the positive charges of polyplexes (+20 mV), resulting in neutrally charged LPPs (0.5--2.5 mV), supporting encapsulation of polyplexes in liposomes. Encapsulation was verified by electron microscopy ([Figures 2](#fig2){ref-type="fig"}B and 2D) and was in accordance with previous studies.[@bib60], [@bib62] A DOPA/PEI molar ratio of 23 was used for further studies. Note that complexes prepared with self-replicative RNA, which is larger than concentional mRNA (10,000 nt for VEE-GFP RNA versus 1,000 nt for GFP RNA), were also under 200 nm and neutral: 180/10 nm and 1/0.9 mV.Figure 1Formation of LPPsTable 1Size and Zeta Potential of PolyplexesPEI/RNA (N/P Ratio)Size (nm)Zeta Potential (mV)4.5172/42−2/56166/1020/97.5165/813/29156/910/3Table 2Size and Zeta Potential of LPPsDOPA/PEI (Molar Ratio)Size (nm)PDIZeta (mV)18186/100.13/0.022.5/1.423190/80.13/0.010.5/0.225188/90.14/0.071/0.932157/160.12/0.021.1/0.5Figure 2LPP Morphology and Stability(A) RNase protection assay: lane 1, RNA; lane 2, RNA + RNase; lane 3, LPPs treated with RNase and dissociated with sulfated dextran (SD). (B) Morphology of LPPs by TEM at low magnification. Scale bar represents 500 nm. (C) Measurement of LPP diameters by DLS after incubation in media 10% FBS at 37°C. (D) Morphology of LPPs by TEM. Scale bar represents 100 nm.

Systemic administration of RNA complexes requires avoiding aggregation or destruction of complexes in physiological fluids and protection from RNase degradation.[@bib1] Protection against RNase degradation was checked by gel electrophoresis ([Figure 2](#fig2){ref-type="fig"}A). Whereas naked RNA was degraded by RNase ([Figure 2](#fig2){ref-type="fig"}A, lane 2), LPP formulation protected it from degradation ([Figure 2](#fig2){ref-type="fig"}A, lane 3).

We monitored the size of LPPs in serum and at 37°C by dynamic light scattering ([Figure 2](#fig2){ref-type="fig"}C). After 6 h incubation, there was no aggregation of LPPs, indicating its stability. Note that LPPs prepared with unPEGylated liposomes aggregated to ≈1 μm in 1 h, confirming PEG-mediated stabilization of the particles in serum as in Buyens et al.[@bib59] and Zhao et al.[@bib63]

*In Cellulo* Transfection Activity {#sec2.2}
----------------------------------

LPPs prepared with 25K PEI and anionic liposomes exhibited a low cytotoxicity (10%--15%) toward murine DCs, similar to that of the lipofectamine messenger max (LFM) control ([Figure 3](#fig3){ref-type="fig"}B). PEI 25K polyplexes were, however, toxic (\>20% decrease in cell metabolism), in agreement with Wang et al.[@bib60] Then, we checked the transfection efficiency with conventional mRNA. Although lipofectamine showed superior transfection efficiency over LPPs at 4 h and 24 h (25% transfected cells versus 2.5% at 4 h and 43% versus 22% at 24 h), transfection efficiency was similar at 48 h post-transfection (27% and 22%, respectively), suggesting differences in expression kinetics due to composition and structure differences in the two kinds of RNA complexes ([Figure 3](#fig3){ref-type="fig"}A).[@bib39], [@bib64], [@bib65]Figure 3LPP Activity in Murine Dendritic Cells *In Cellulo*(A) DC transfection efficiency of PEI, LPP, and LFM formulations made with 2 μg GFP mRNA. (B) Cell viability of DCs 24 h after transfection with PEI 25K polyplexes, LPPs, or lipofectamine messenger max (LFM) complexes. (C) DC transfection efficiency of LPPs or LFM made with 2 μg RepRNA.

Transfection of murine DCs with LPPs prepared with GFP RepRNA resulted in 14%--16% transfected cells through 24 h to 72 h post-transfection ([Figure 3](#fig3){ref-type="fig"}C). Although low, this percentage is in agreement with the 11%--21% DC transfection using lipids[@bib66] and with the 16% pluripotent stem cell transfection using RepRNA GFP.[@bib67] No significant difference in transfection efficiency was observed at 24 h between LPPs and LFM (14% versus 18%, respectively). However, LFM yielded higher percentages of GFP-expressing cells at 48 h (27% versus 15% for LPPs) and 72 h (27% versus 16%). A low *in vitro* transfection efficiency of DCs does not imply an *in vivo* inefficiency. Indeed, lipidic nanoparticles prepared with luciferase RepRNA were not able to transfect DC 2.4 cells[@bib29] but were capable of protective anti-influenza vaccination. This reflects the weak i*n vitro*/*in vivo* correlation because of the increased complexity of the biological and physiological mechanisms at play in an animal model compared to a monolayer culture of a cell line.[@bib68], [@bib69] RepRNA expression in DC 2.4 cells after LPP transfection suggests an immunological role for LPP.

*In Vivo* Evaluation of LPP {#sec2.3}
---------------------------

The next set of experiments aimed to demonstrate the *in vivo* expression of RNA delivered using LPPs. To demonstrate the versatility of the LPP platform, we evaluated the delivery of both conventional mRNA and RepRNA ([Figure 4](#fig4){ref-type="fig"}). Conventional RNA was administered by an i.v. route to enhance accumulation of mRNA in the spleen and favor endocytosis of LPPs by splenic DCs, as in our previous studies[@bib14], [@bib15], [@bib70] and as in clinical studies (Heesch et al., 2016, Cancer Res., abstract).[@bib16], [@bib24] RepRNA was injected i.m. to allow localized amplification of RepRNA, rather than its dispersion after i.v. injection, and because most RepRNA vaccines have been injected i.m. in mice, macaques, and humans.[@bib22], [@bib29], [@bib36], [@bib71], [@bib72], [@bib73] Moreover, the i.m. route is a suitable route for the delivery of mRNA to lymph node DCs.[@bib74]Figure 4*In Vivo* RNA Expression after LPP-RNA Administration(A) Percentages of murine splenic DC transfection after intravenous injection of LPP-RNA complexes (20 μg in 250 μL). (B) Bioluminescence imaging of BALB/c mice at various days following intramuscular injection of LPP-RepRNA complexes (5 μg in 50 μL); mean luminescence values are also shown in photons/seconds/cm^2^.

The evaluation of splenic DC transfection *in vivo* was performed 24 h and 48 h after i.v. injection of LPPs made with GFP mRNA. DCs were isolated from the spleen, and GFP expression was examined by flow cytometry ([Figure 4](#fig4){ref-type="fig"}A). LPP administration resulted in transfection of 5% at 24 h and 7% of splenic DCs at 48 h. Our data are in agreement with the 10% splenic DC transfection obtained with positively-charged mannosylated LPPs (+43 mV),[@bib7], [@bib15] the 5% GFP expressing splenic DCs after i.v. injection of positively-charged DOTAP lipoplexes (+27 mV),[@bib38] and the 6% splenic DC transfection with negatively-charged lipoplexes (−20 mV).[@bib16] They are also similar to results on *in vivo* DC transfection using other administration routes with 5% inguinal lymph node DC transfection after subcutaneous injection of negatively charged (−10 mV) LNPs.[@bib39]

RepRNA-LPPs were i.m. injected (5 μg RepRNA dose) before monitoring signal by luminescence imaging ([Figures 4](#fig4){ref-type="fig"}B and 4C). Durable luciferase expression was detectable at the site of injection from day 3 to day 14. The expression peaked at day 7 to day 10 before dropping at day 14 to the value at day 3. The delay observed in reporter gene expression together with a maximal expression at day 7 followed by a sharp signal decrease is in accordance with previous results of i.m. RepRNA delivery.[@bib29], [@bib36], [@bib71] The later onset of expression may be attributed to the delay necessary for expression of the replicase polyprotein, its cleavage to form the replicase complex, and amplification of RNA. The sharp decrease of expression detected can be attributed to the exhaustion and/or death of RepRNA-transfected cells.[@bib26], [@bib36] No signal was detected after injection of LFM-RepRNA complexes, albeit this transfection reagent is not intended for *in vivo* use (data not shown).

Immunogenicity of LPPs {#sec2.4}
----------------------

Upon demonstration of *in vivo* expression, we explored the immunological potentiality of LPP-RepRNA complexes ([Figure 5](#fig5){ref-type="fig"}). Using adoptive transfer, we measured the induction of lymph node hemagglutinin (HA)-specific CD4 ([Figure 5](#fig5){ref-type="fig"}A) and CD8 ([Figure 5](#fig5){ref-type="fig"}B) cells. Induction of HA-specific T cells was also evaluated in the spleen ([Figure 5](#fig5){ref-type="fig"}C). Vaccination by i.m. route with LPP-RepRNA encoding HA resulted in the expansion of lymph node antigen-specific CD4^+^ T cells (3.5%) and CD8^+^ T cells (5.5%) as shown in [Figures 5](#fig5){ref-type="fig"}A and 5B. Administration of LPP-RepRNA also induced specific lymphocytes in the spleen, with a stimulation index superior to free RNA + adjuvant ([Figure 5](#fig5){ref-type="fig"}C). Lymphocytes induced by vaccination were functional, as evidenced by the 1.6-fold higher counts of antigen-specific CD4^+^ and CD8^+^ T cells secreting IFN-γ in the spleens of mice vaccinated with LPP-RepRNA over free RNA ([Figure 5](#fig5){ref-type="fig"}D). Induction of both CD4 and CD8 responses after RepRNA administration is consistent with previous data on i.m. vaccination with RepRNA lipidic nanoparticles.[@bib71]Figure 5Immunogenicity of LPP-RepRNA(A and B) Mice were vaccinated by intramuscular injection of LPP-RepRNA. We analyzed the induction of HA-specific T cells in the lymph nodes, both CD4 (A) and CD8 (B). Stimulation indexes of splenocytes from vaccinated mice after re-stimulation with HA peptide (C) and counts of IFN-γ secreting splenic T cells. \*\*p \< 0.01 compared with RepRNA.

Materials and Methods {#sec3}
=====================

All reagents were purchased from Sigma (St. Quentin Fallavier, France) unless otherwise stated. The mMESSAGE mMACHINE T7 ULTRA Transcription Kit, was purchased from Thermo Fisher Scientific (Montigny-le-Bretonneux, France). DOPE, DSPE-PEG, DOPA, and 16:0 PA-PEG3-mannose were from Avanti Polar Lipids (Alabaster, AL, USA).

Plasmids {#sec3.1}
--------

The pGEM4Z-luc and pGEM4Z-EGFP plasmids used for the preparation of luciferase and EGFP RNA have been previously described.[@bib7] The self-replicative RNA plasmid encoding GFP, pT7-VEE-GFP was a gift from Steven Dowdy (Addgene plasmid \#58977). This plasmid is derived from Venezuelan equine encephalitis virus.[@bib75] HA from influenza was synthetized by Genscript (Piscataway, NJ, USA) and inserted into previously digested pT7-VEE-GFP to replace GFP by HA to obtain pT7-VEE-HA. For the pT7-VEE-luc plasmid, we replaced the GFP of pT7-VEE-GFP with luc from pGEM4Z-luc. Plasmid DNA (pDNA) used in this study was amplified in *E. coli* DH5α and purified using an Endofree Plasmid Mega Kit (QIAGEN, Courtaboeuf, France).

*In Vitro* Transcription {#sec3.2}
------------------------

Anti-reverse cap analog (ARCA)-capped RNA with a poly(A) tail was produced by *in vitro* transcription using the T7 mMessage mMachine kit as described in Lin et al.[@bib6] and Perche et al.[@bib7] The RNA concentration was determined by absorbance at 260 nm; RNA had 260:280 ratios ≥2 and was stored at --80°C in endonuclease-free water in small aliquots.

Cell Culture {#sec3.3}
------------

DC 2.4 murine DCs were a gift from Kenneth L. Rock[@bib76] and were grown at 37°C in a humidified atmosphere containing 5% CO~2~ in RPMI1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin (Fischer Bioblock, Illkirch, France). Cells were mycoplasma-free, as evidenced by MycoAlert Mycoplasma Detection Kit (Lonza, Levallois Perret, France).

Liposome Preparation {#sec3.4}
--------------------

Liposomes were prepared by thin-film hydration as in Apte et al.[@bib77] Both PEGylated and unPEGylated liposomes were prepared. A chloroform solution of 40% DOPA, 40% DOPE, 10% PA-PEG3-Man, and 10% DSPE-PEG2000 (molar percentages) was evaporated at 50°C in a rotary evaporator to form lipid films. Lipid films were hydrated with HEPES 10 mM pH 7.4 10% sucrose at a final lipid concentration of 5.4 mM. Liposomes were then sonicated for 15 min at 20°C at 37 kHz using an ultrasonic bath (Fischer Bioblock Scientific, Illkirch, France). Liposomes were then downsized by stepwise extrusion through 0.4 and 0.2 μm pore-size filters using a mini-extruder from Avanti Polar Lipids.

Preparation of mRNA/PEI/Liposome LPPs {#sec3.5}
-------------------------------------

LPPs were prepared according to a procedure modified from Wang et al.[@bib60] Instead of mixing polyplexes with a dried lipid film followed by sonication and extrusion, we mixed polyplexes with liposomes. To prepare LPPs, RNA was mixed with branched PEI of 25K in HEPES 10 mM pH 7.4 10% sucrose at an N/P ratio of 6 at room temperature for 20 min, allowing for polyplex formation. Note that PEI solution was added to RNA solution, as the order of addition is important for LPP formation.[@bib51] Then, different amounts of liposomes were added to polyplexes at DOPA/PEI molar ratios between 12 and 38.

LPP Characterization {#sec3.6}
--------------------

The size and zeta potential of LPPs were determined by dynamic light scattering (DLS) using an SZ-100 nanoparticle analyzer (Horiba, Longjumeau, France). LPP structure was analyzed by transmission electron microscopy (TEM) using a Philips CM20/STEM electron microscope operating at 50 kV (Centre de Microscopie Electronique, Université d'Orléans, France). TEM samples were prepared according to the technique of negative staining using uranyl acetate. The basis of the method is to surround the light atoms sample with a dense stain to create TEM contrast. 5 μL LPP solution in HEPES buffer was deposited on a carbon-coated copper grid for 5 min and then adsorbed with filter paper. 5 μL uranyl acetate 2% in endonuclease-free water was then deposited on the grid for 10 s and then adsorbed. Samples were dried at room temperature for 20 min before TEM observation.

The concentration of mannosylated lipids in liposomes was estimated by a resorcinol/sulfuric acid assay as described in Perche et al.[@bib7] The principle is that, under acidic conditions, sugars dehydrate, forming a furfural derivative, which condenses with resorcinol to yield a chromogenic compound with an absorbance at 430 nm. Briefly, samples or standards are deposited into 96-well microplates before successive addition of a resorcinol solution in water and a solution of 75% sulfuric acid. The plate is then heated at 90°C during 30 min before reading the absorbance at 430 nm.

RNase Protection Assay {#sec3.7}
----------------------

RNase protection assay was performed according to Perche et al.[@bib78] Samples containing 2 μg mRNA were incubated with 5 U of RNase A/T1 Mix (Thermo scientific) for 2 h at 37°C. The RNase was then inactivated with Protector RNase Inhibitor (Roche) before complex dissociation using sulfated dextran (10% of final volume). Then, samples were analyzed on a 1% agarose-formaldehyde gel containing ethidium bromide. Gels were imaged using a Gene Flash imager (Syngene, Cambridge, UK).

Transfections {#sec3.8}
-------------

Cells were transfected with either LPP or LFM (Thermo Fisher Scientific) as commercial standard at 70%--80% confluency in 24-well plates containing 2 μg RNA encoding GFP per well. Transfection efficiency was evaluated at 4 h, 24 h, or 48 h after transfection. The cell-associated fluorescence intensity was measured with a flow cytometer (FACSort; Becton Dickinson, Franklin Lakes, NJ, USA) with λ~ex~ = 488 nm; λ~em~ = 530 ± 30 nm. The fluorescence intensity was expressed as the mean fluorescence intensity of 10,000 events.

*In Vitro* Cytotoxicity {#sec3.9}
-----------------------

Cytotoxicity was evaluated performing an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay as described in Perche et al.[@bib70] This assay is based on the reduction of soluble MTT into insoluble formazan (with absorbance at 570 nm) by cellular oxidoreductases. MTT (200 μL of a 5 mg/mL solution in PBS) was added to the cells in 1 mL culture medium, and cells were incubated for 3 h at 37°C. Cells were then washed with PBS, and the MTT converted in formazan was solubilized with acidic isopropanol (99.5%). The cell viability was expressed as a percentage of absorbance of untransfected cells cultured in the same conditions.

*In Vivo* Evaluation of Splenic DC Transfection {#sec3.10}
-----------------------------------------------

Specific pathogen-free female BALB/c (8--11 weeks) mice were obtained from Janvier (Le Genest St Isle, France) and kept in isolated ventilated cages. All animal studies were approved by the French Ministry of Agriculture for experiments with laboratory animals.

Mice received 20 μg EGFP mRNA/LPP in HEPES 5% sucrose by i.v. injection in the tail vein (volume of 250 μL). Control mice received 250 μL HEPES 5% sucrose. Evaluation of splenic DC transfection was carried out as described in Perche et al.[@bib7] Spleens were harvested 24 h or 48 h after injection. Splenic cells were isolated and labeled with magnetic anti-mouse CD11c antibodies (Miltenyi Biotec SAS, Paris, France), which bound to DCs and were enriched by immunomagnetic selection using MACS MS columns (Miltenyi Biotec SAS) according to the manufacturer's protocol. Then, cells were stained with BV711-labeled anti-mouse CD11c antibodies (Miltenyi Biotec SAS), and at least 40,000 cells were analyzed with a FORTESSA X20 flow cytometer (Becton Dickinson) with λex = 488 nm, λem = 530/30 nm for EGFP fluorescence and λex = 405 nm, λem = 710/50 nm for BV711 fluorescence. BV711 is a Horizon Brilliant Violet tandem fluorophore (Beckton Dickinson) of BD Horizon BV421 with a maximum λex at 405 nm and an acceptor dye with a maximum λem at 711 nm.

Measurement of *In Vivo* Luminescence {#sec3.11}
-------------------------------------

Mice were i.m.-injected with LPPs prepared with 5 μg RepRNA encoding luciferase (50 μL injection volume). Animals were imaged as described in Lin et al.[@bib6] using an IVIS Lumina system imaging system (PerkinElmer, Villebon-sur-Yvette, France) 5 min after intraperitoneal injection of 200 μL D-Luciferin substrate at the CIPA (Centre d'Imagerie du Petit Animal, Orléans, France).

Animals for Functional Evaluation {#sec3.12}
---------------------------------

Six- to eight-week-old female BALB/c mice were purchased either from Harlan Winkelmann (Germany) or Janvier Labs (France) and maintained in the animal care facility of the Helmholtz Centre for Infection Research. All animal experiments were approved by the Helmholtz-Zentrum für Infektionsforschung (HZI) ethical board and conducted in accordance with the regulations of the local government of Lower Saxony (Germany, 33-42502-04-13/1281 and 33-42502-04-16/2118).

Adoptive Transfer {#sec3.13}
-----------------

For the adoptive transfer experiments, T cell receptor (TCR)-HA transgenic mice were used as described in Englezou et al.[@bib23] Briefly, the proliferation of antigen-specific CFSE-labeled (carboxyfluorescein succinimidyl ester) T cells derived from TCR-HA mice were transferred by i.v. injection to naive BALB/c mice. Then, mice were vaccinated 24 h after injection of the CFSE-labeled splenocytes with LPPs prepared with HA RepRNA co-admininistered with c-di-AMP adjuvant. Proliferation, via loss of CFSE staining of CD4^+^ and CD8^+^ T cells, was determined by flow cytometry.

Immunization {#sec3.14}
------------

Mice were immunized three times with 10 μg HA RepRNA/LPPs co-administered with c-di-AMP (10 μg) by i.m. route (50 μL injection volume), with one immunization (day 0) and two boosts (days 21 and 42). Two weeks later, spleens of vaccinated mice were aseptically removed, cell suspensions using pools of spleen cells of different immunized groups were prepared, and erythrocytes were lysed by a short-term incubation (maximum of 2 min) in ACK lysis buffer (0.15 M NH~4~Cl, 1.0 M KHCO~3~, 0.1 mM EDTA, pH 7.2). Then cells were washed twice and adjusted to 2 × 10^6^ cells/mL in complete RPMI medium (containing 10% fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin; GIBCO, UK). Then splenocytes (2 × 10^7^ cells/mL) were incubated (37°C, 5% CO~2~) in RPMI containing the HA antigen (\#13/164, 200 ng HA/mL) or no antigen to determine the basal cytokine production. Viable singlet leukocytes were gated for CD3, CD4, and CD8 and subsequently analyzed for the expression of intracellular IFN-γ.

Measurement of Cellular Proliferation {#sec3.15}
-------------------------------------

To study T cell polarization, we used CD4 and CD8 T cells from TCR-HA mice. These mice express rearranged TCR α/β chains specific for the MHC class II I-Ed restricted determinant site from influenza virus A/PR/8/34 HA (PR8 HA).[@bib37] *In vitro*-enriched CD4^+^ and CD8^+^ T cells from TCR-HA transgenic animals were adoptively transferred to normal BALB/c mice. Recipient mice received 2--3 × 10^6^ CFSE-labeled cells by tail vein injection and were immunized by i.m. injection of 50 μL of 10 μg HA RepRNA/LPP co-administered with c-di-AMP (10 μg). After 7 days, the mice were sacrificed, and spleens and draining inguinal or cervical lymph nodes (LNs) were aseptically removed. Lymph nodes were filtered through a mesh to get a single suspension. After two wash steps with PBS (centrifugation with 200 × *g*/5 min), lymph node cells were ready to be used for subsequent FACS analysis or CFSE staining. The splenocyte pools of each group were cultured in the presence of different concentrations of H1N1 (\#13/164) with enhanced HA concentrations of 0.1 up to 1 μg/mL; controls received 5 μg/mL concanavalin A as described in Ebensen et al.[@bib79] After staining for CD3, CD4, CD8, CD19, and the live/dead marker (LIVE/DEAD Fixable Dead Cell Stain Kit from Invitrogen) as a marker of viability, cells were fixated with 2% paraformaldehyde (PFA). Readout was performed by flow cytometry.

Multifunctional T Cells {#sec3.16}
-----------------------

Splenocytes (2 × 10^7^ cells/mL) were incubated (37°C, 5% CO~2~) in RPMI containing the HA antigen (H1N1, 200 ng HA/mL) or no antigen to determine the basal cytokine production. Viable singlet leukocytes were gated for CD3^+^ CD4^+^ or CD3^+^ CD8^+^ and subsequently analyzed for the expression of intracellular IFN-γ by flow cytometry as described in Ebesen et al.[@bib79]

Statistical Analysis {#sec3.17}
--------------------

The data were tested for statistical significance using ANOVA. All numerical data are expressed as mean ± SD, n = 3. Any p value less than 0.05 was considered statistically significant.

Conclusions {#sec3.18}
-----------

The results of this study are, to the best of our knowledge, the first on conventional and self-replicative RNA expression *in vivo* using the same formulation. LPPs are stable in serum-containing media, transfect DCs *in cellulo* and their injection results in reporter gene expression *in vivo* and, to the induction of antigen-specific immune responses. Our data on conventional RNA delivery as LPP-RNA complexes corroborates the reported splenic DC transfection after i.v. administration of negative-to-neutral lipoplexes.[@bib16], [@bib80] Moreover, i.m. injection of LPP-RepRNA complexes led to sustained reporter gene expression *in vivo* and the induction of functional antigen-specific T cells when LPP-RepRNA coded for an influenza antigen.

Taken together, our strategy has the potential for the delivery of both conventional and self-replicative RNA, providing a platform for various therapeutic applications. Determination of the therapeutic activity of i.v. injected LPP-RNA complexes and locally injected LPP-RepRNA complexes will be our prime focus in the future.
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